Eliem Therapeutics Inc (ELYM)
7.59
-0.07
(-0.91%)
USD |
NASDAQ |
May 31, 16:00
7.68
+0.09
(+1.19%)
Pre-Market: 20:00
Eliem Therapeutics SG&A Expense (Quarterly): 1.914M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 1.914M |
December 31, 2023 | 1.995M |
September 30, 2023 | 2.125M |
June 30, 2023 | 3.026M |
March 31, 2023 | 17.72M |
December 31, 2022 | 4.627M |
September 30, 2022 | 4.49M |
June 30, 2022 | 4.932M |
March 31, 2022 | 4.872M |
Date | Value |
---|---|
December 31, 2021 | 3.824M |
September 30, 2021 | 3.394M |
June 30, 2021 | 2.914M |
March 31, 2021 | 2.218M |
December 31, 2020 | 1.537M |
September 30, 2020 | 0.312M |
June 30, 2020 | 0.248M |
March 31, 2020 | 0.328M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.248M
Minimum
Jun 2020
17.72M
Maximum
Mar 2023
3.557M
Average
2.914M
Median
Jun 2021
SG&A Expense (Quarterly) Benchmarks
Alpine Immune Sciences Inc (DELISTED) | 7.271M |
Candel Therapeutics Inc | 3.80M |
Cyclacel Pharmaceuticals Inc | 1.582M |
Lipocine Inc | 1.576M |
GlycoMimetics Inc | 5.09M |